#EarningsWithETNOW | Strides Pharma Science Q2 (YoY)

- Loss of Rs 85 cr vs PAT of Rs 79 cr
- Revenue at Rs 736 cr vs Rs 797 cr
- Reported EBITDA at Rs 1 cr vs Rs 165 cr
- R&D investment in Q2 at Rs 22 cr

@strides_pharma #StridesPharmaQ2